Acute Pancreatitis : Comparison of Various Scores in Predicting Severity and Outcome

February 12, 2024 updated by: Ali Bakr Ahmed, Sohag University
The study will make a comparison between Various severity scoring systems that has been designed to assess the severity and predict prognosis in acute pancreatitis

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

the study will evaluate the relationship between homeostatic model assessment of insulin resistance , bedside index of severity score and the harmless acute pancreatitis score and prognosis of acute pancreatitis ,will compare of these scores in predicting severity of acute pancreatitis and will compare of these scores in predicting outcome of acute pancreatitis.

Study Type

Observational

Enrollment (Estimated)

50

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

  • age <18 years old,
  • patients with metastatic tumor
  • late stage of liver cirrhosis
  • active tuberculosis
  • refractory heart failure
  • previous transplantation
  • immunosuppressive therapy
  • pregnancy
  • patients with chronic pancreatitis or pancreas carcinoma

Description

Inclusion Criteria:

  • Any patient with 18 years or above and met criteria for diagnosis of acute pancreatitis will be eligible for the study.

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of various scores in predicting severity and outcome in patients with acute pancreatitis. 1.Homeostatic model assessment of insulin resistance. 2.The harmless acute pancreatitis score.
Time Frame: within 18 months

  1. Homeostatic model assessment of insulin resistance it measure severity of insulin resistance, there is an association between insulin resistance and severity of acute pancreatitis.

    It is defined as fasting glucose (mmol/L) × fasting insulin (μmol/L)/22.5] or [fasting glucose (mg/dL) × fasting insulin (μmol/L) Reference index levels is ≤ 2. If index ˃ 2 indicate presence of insulin resistance

  2. The harmless acute pancreatitis score Harmless acute pancreatitis score contains three parameters - blood urea nitrogen, levels of serum creatinine and haematocrit . The patient is classified as harmless acute pancreatitis score negative (-) if they have blood urea nitrogen <25 mg/dL, serum creatinine levels < 2 mg/dL, and haematocrit levels of <43% for males and <39.6% for females at the time of admission. The patient is considered positive (+) if any one of the above parameters is positive.
within 18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 20, 2024

Primary Completion (Estimated)

August 20, 2025

Study Completion (Estimated)

August 20, 2025

Study Registration Dates

First Submitted

January 2, 2024

First Submitted That Met QC Criteria

January 31, 2024

First Posted (Actual)

February 5, 2024

Study Record Updates

Last Update Posted (Estimated)

February 14, 2024

Last Update Submitted That Met QC Criteria

February 12, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-23-12-05MD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe